Drug Type Antibody drug conjugate (ADC) |
Synonyms anti-HER2 ADC(Shanghai Fudan-Zhangjiang Bio-Pharmaceutical), 抗Her2抗体偶联BB05, 抗Her2抗体偶联BB05 + [3] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 23 Apr 2024 |